X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (31) 31
index medicus (30) 30
female (24) 24
male (24) 24
middle aged (24) 24
aged (21) 21
oncology (21) 21
adult (20) 20
antibodies, monoclonal - administration & dosage (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
treatment outcome (13) 13
aged, 80 and over (11) 11
colorectal neoplasms - drug therapy (11) 11
colorectal neoplasms - genetics (11) 11
colorectal neoplasms - pathology (11) 11
antibodies, monoclonal - therapeutic use (10) 10
neoplasm metastasis (10) 10
prognosis (10) 10
ras proteins - genetics (10) 10
c-met (9) 9
cancer (9) 9
chemotherapy (9) 9
neoplasm staging (9) 9
proto-oncogene proteins - genetics (9) 9
proto-oncogene proteins p21 (9) 9
antibodies, monoclonal - adverse effects (8) 8
disease-free survival (8) 8
mutation (8) 8
young adult (8) 8
animals (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
care and treatment (7) 7
cetuximab (7) 7
chemistry (7) 7
dose-response relationship, drug (7) 7
human necessities (7) 7
hygiene (7) 7
investigating or analysing materials by determining theirchemical or physical properties (7) 7
measuring (7) 7
medical or veterinary science (7) 7
metallurgy (7) 7
metastasis (7) 7
monoclonal antibodies (7) 7
organic chemistry (7) 7
peptides (7) 7
physics (7) 7
preparations for medical, dental, or toilet purposes (7) 7
receptor, epidermal growth factor - antagonists & inhibitors (7) 7
testing (7) 7
1st-line treatment (6) 6
amg 102 (6) 6
carcinoma (6) 6
colorectal neoplasms - mortality (6) 6
expression (6) 6
hematology, oncology and palliative medicine (6) 6
hepatocyte growth-factor (6) 6
survival rate (6) 6
antibodies, monoclonal - pharmacokinetics (5) 5
antineoplastic agents (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
bevacizumab (5) 5
cetuximab plus irinotecan (5) 5
cisplatin (5) 5
cisplatin - administration & dosage (5) 5
colorectal cancer (5) 5
fluorouracil (5) 5
fluorouracil - administration & dosage (5) 5
follow-up studies (5) 5
hepatocyte growth factor (5) 5
kaplan-meier estimate (5) 5
panitumumab (5) 5
proportional hazards models (5) 5
research (5) 5
survival (5) 5
survival analysis (5) 5
amplification (4) 4
analysis (4) 4
antimitotic agents (4) 4
article (4) 4
biomarkers, tumor - genetics (4) 4
coronary circulation (4) 4
dogs (4) 4
echocardiography (4) 4
fluorouracil - adverse effects (4) 4
head and neck neoplasms - mortality (4) 4
head and neck neoplasms - pathology (4) 4
hepatocyte growth factor - blood (4) 4
human-papillomavirus (4) 4
kras (4) 4
leucovorin - administration & dosage (4) 4
mutations (4) 4
open-label (4) 4
oropharyngeal cancer (4) 4
retrospective studies (4) 4
adenocarcinoma - pathology (3) 3
adolescent (3) 3
advanced solid tumors (3) 3
altruism (3) 3
altruisme (3) 3
altruistic behavior (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 21, pp. 2240 - 2247
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2013, Volume 369, Issue 11, pp. 1023 - 1034
Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,... 
SURVIVAL | 1ST-LINE TREATMENT | LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | RANDOMIZED PHASE-III | CETUXIMAB PLUS IRINOTECAN | BRAF | KRAS CODON 12 | FLUOROURACIL | CHEMOTHERAPY | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Membrane Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - therapeutic use | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Fluorouracil - therapeutic use | Neoplasm Metastasis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Leucovorin - therapeutic use | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Organoplatinum Compounds - therapeutic use | Care and treatment | Dosage and administration | Research | Gene mutations | Panitumumab | Colorectal cancer | Hypothesis testing | Medical research | Statistical analysis | Epidermal growth factor receptors | Colorectal carcinoma | Metastasis | Cancer therapies | Survival | Patients | Metastases | Studies | Hypotheses | Chemotherapy | Epidermal growth factor | Oxaliplatin | Testing laboratories | Medical prognosis | Biomarkers | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4697 - 4705
Purpose Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved... 
KRAS MUTATIONS | MCRC | ONCOLOGY | STATISTICS | CETUXIMAB PLUS IRINOTECAN | CHEMOTHERAPY CT | OPEN-LABEL | COMBINATION | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Colorectal Neoplasms - mortality | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 697 - 710
Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | P16 | ONCOLOGY | COLORECTAL-CANCER | OROPHARYNGEAL CANCER | HUMAN-PAPILLOMAVIRUS | P16(INK4A) | SUBSET | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP | PLUS FLUOROURACIL | Immunohistochemistry | South America | Head and Neck Neoplasms - virology | Prospective Studies | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Neoplasm Recurrence, Local - virology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | North America | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Head and Neck Neoplasms - chemistry | Neoplasm Metastasis | Carcinoma, Squamous Cell - mortality | Cyclin-Dependent Kinase Inhibitor p16 - analysis | Fluorouracil - administration & dosage | Time Factors | Female | Retrospective Studies | Biomarkers, Tumor - analysis | Europe | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Squamous Cell - chemistry | Treatment Outcome | Papillomaviridae - isolation & purification | Neoplasm Recurrence, Local - chemistry | Head and Neck Neoplasms - pathology | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Biopsy | Carcinoma, Squamous Cell - secondary | Aged | Head and Neck Neoplasms - mortality | Care and treatment | Relapse | Carcinoma | Monoclonal antibodies | Product development | Metastasis | Cisplatin | Cancer | Diseases | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 9, pp. 1007 - 1018
Summary Background Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumour growth and metastasis. Rilotumumab is a fully human,... 
Hematology, Oncology and Palliative Medicine | AMPLIFICATION | PHARMACOKINETICS | ONCOLOGY | HEPATOCYTE GROWTH-FACTOR | C-MET | MONOCLONAL-ANTIBODY | CIRCULATING LEVEL | AMG 102 | CANCER | EXPRESSION | CARCINOMA | Confidence Intervals | Adenocarcinoma - pathology | Esophagogastric Junction - drug effects | Prognosis | Capecitabine | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Stomach Neoplasms - pathology | Dose-Response Relationship, Drug | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Fluorouracil - adverse effects | Neoplasm Invasiveness - pathology | Adult | Deoxycytidine - adverse effects | Female | Double-Blind Method | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Proportional Hazards Models | Esophagogastric Junction - pathology | Survival Rate | Treatment Outcome | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Epirubicin - therapeutic use | Aged | Neoplasm Staging | Stomach Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Epirubicin - adverse effects | Monoclonal antibodies | Anthracyclines | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4706 - 4713
Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in... 
SURVIVAL | 1ST-LINE TREATMENT | CONTROLLED-TRIAL | SUPPORTIVE CARE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | KRAS | OXALIPLATIN | FAILURE | CHEMOTHERAPY | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Index Medicus
Journal Article
Journal Article
Science Translational Medicine, ISSN 1946-6234, 02/2014, Volume 6, Issue 224, pp. 224ra24 - 224ra24
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain... 
Humans | Middle Aged | Male | Young Adult | Neoplasm Metastasis | Neoplasms - blood | DNA, Neoplasm - blood | Neoplasms - genetics | Aged, 80 and over | Adult | Female | Aged | Neoplasms - pathology | MEDICINE, RESEARCH & EXPERIMENTAL | CELL BIOLOGY | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 208 - 220
Journal Article